Abstract
Disclosed are compounds of Formula I and their use as inhibitors of the viral protease non-structural protein 5 (NSP5). Typically, the NSP5 is derived from a coronavirus, more typically from SARS-CoV-2. More particularly, the invention relates to compounds of Formula (I) and their use for treating or inhibiting the development of a condition in which inhibiting NSP5 activity is associated with effective treatment or inhibition, including a coronavirus infection, for treating or inhibiting the development of a condition associated with a coronavirus infection, for treating or inhibiting the development of neurological symptoms of, and/or neurological complications associated with, a coronavirus infection and for treating or inhibiting the development or progression of long COVID following SARS-CoV-2 infection.
| Original language | English |
|---|---|
| Patent number | WO2024026540 |
| IPC | C07D 471/04 A I,A61K 31/4545 2006.1,A61K 31/517 2006.1,A61P 31/14 2006.1,C07D 401/14 2006.1,C07D 409/14 2006.1 |
| Priority date | 5/08/22 |
| Publication status | Published - 8 Feb 2024 |